Statement: Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial, this is due to the significant difference in cohort size.
Primary_evidence: Adverse Events 1:   Total: 10/41 (24.39%)   Cardiac failure * 1/41 (2.44%)   Pericardial effusion * 1/41 (2.44%)   Ascites * 1/41 (2.44%)   Diarrhoea * 0/41 (0.00%)   Dysphagia * 0/41 (0.00%)   Large intestinal obstruction * 0/41 (0.00%)   Lung infection * 1/41 (2.44%)   Pneumonia * 1/41 (2.44%)   Sepsis * 1/41 (2.44%)   Ejection fraction decreased * 2/41 (4.88%)   Neck pain * 1/41 (2.44%) Adverse Events 2:   Total: 8/37 (21.62%)   Cardiac failure * 0/37 (0.00%)   Pericardial effusion * 0/37 (0.00%)   Ascites * 1/37 (2.70%)   Diarrhoea * 1/37 (2.70%)   Dysphagia * 1/37 (2.70%)   Large intestinal obstruction * 1/37 (2.70%)   Lung infection * 0/37 (0.00%)   Pneumonia * 0/37 (0.00%)   Sepsis * 0/37 (0.00%)   Ejection fraction decreased * 0/37 (0.00%)   Neck pain * 0/37 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 3/41 (7.32%)   ANEMIA 1/41 (2.44%)   FEBRILE NEUTROPENIA 1/41 (2.44%)   LEUKOPENIA 1/41 (2.44%)   NEUTROPENIA 2/41 (4.88%)   THROMBOCYTOPENIA 2/41 (4.88%)   DIARRHEA 1/41 (2.44%)   DYSPEPSIA 1/41 (2.44%)   FLATULENCE 1/41 (2.44%)   MUCOSITIS 1/41 (2.44%)   NAUSEA 2/41 (4.88%)   VOMITING 2/41 (4.88%)   EDEMA 1/41 (2.44%)   FATIGUE 2/41 (4.88%)   PHARYNGITIS 1/41 (2.44%)